Monday, 14 October 2019

Hyphens Pharma inks MoU with A*STAR for Derma research

22 March 2019 | News

Hyphens intends to develop innovative and differentiated dermatological products to address unmet market needs.

Hyphens is currently licensing sugar-based surfactant micro-emulsions technology from A*STAR’s Institute of Chemical and Engineering Sciences (ICES).

By leveraging A*STAR’s research and development capabilities, it is envisioned that this MoU will enable Hyphens to develop innovative and differentiated dermatological products to address unmet market needs.

Hyphens is a Singapore-headquartered ASEAN specialty pharma company. Operating in six countries across the region, Hyphens has a strong medical, regulatory and commercial capability. Dermatology is a key therapeutic focus field where Hyphens markets products under the brands “Ceradan” and “TDF”.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Asia-Pacific dominating the global digital transformation in healthcare market?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls